PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT3796306

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
GBP IP, LLC	08/01/2014

RECEIVING PARTY DATA

Name:	MILTENYI BIOTEC TECHNOLOGY, INC.
Street Address:	910 CLOPPER ROAD, SUITE 200S
City:	GAITHERSBURG
State/Country:	MARYLAND
Postal Code:	20878

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	11460136

CORRESPONDENCE DATA

Fax Number: (540)477-2571

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 5403580448

Email: jackie@miltenyibiotec.com
Correspondent Name: JAQUELIN K. SPONG
Address Line 1: 14412 SENEDO ROAD

Address Line 4: MOUNT JACKSON, VIRGINIA 22842

ATTORNEY DOCKET NUMBER:	MBTI_LEN_004
NAME OF SUBMITTER:	JAQUELIN K. SPONG
SIGNATURE:	/Jaquelin K. Spong/
DATE SIGNED:	03/23/2016

Total Attachments: 15

source=1275217-V8-PATENT ASSIGNMENT (Execution)#page1.tif source=1275217-V8-PATENT ASSIGNMENT (Execution)#page2.tif source=1275217-V8-PATENT ASSIGNMENT (Execution)#page3.tif source=1275217-V8-PATENT ASSIGNMENT (Execution)#page4.tif source=1275217-V8-PATENT ASSIGNMENT (Execution)#page5.tif source=1275217-V8-PATENT ASSIGNMENT (Execution)#page6.tif

PATENT 503749661 REEL: 038078 FRAME: 0807

ACTECATIVE DATENT ACCIONNATIVE (For subsection)	
source=1275217-V8-PATENT ASSIGNMENT (Execution)#page7.tif	
source=1275217-V8-PATENT ASSIGNMENT (Execution)#page8.tif	
source=1275217-V8-PATENT ASSIGNMENT (Execution)#page9.tif	
source=1275217-V8-PATENT ASSIGNMENT (Execution)#page10.tif	
source=1275217-V8-PATENT ASSIGNMENT (Execution)#page11.tif	
source=1275217-V8-PATENT ASSIGNMENT (Execution)#page12.tif	
source=1275217-V8-PATENT ASSIGNMENT (Execution)#page13.tif	
source=1275217-V8-PATENT ASSIGNMENT (Execution)#page14.tif	
source=1275217-V8-PATENT ASSIGNMENT (Execution)#page15.tif	

PATENT ASSIGNMENT

THIS PATENT ASSIGNMENT (this "<u>Assignment</u>") is entered into as of August 1, 2014 (the "<u>Effective Date</u>") by and among **LENTIGEN CORPORATION**, a Delaware corporation ("<u>Lentigen</u>"), **GBP IP CORP.**, a Delaware corporation ("<u>GBP</u>" and, together with Lentigen, "<u>Assignors</u>" and each individually, an "<u>Assignor</u>"), and **MILTENYI BIOTEC TECHNOLOGY, INC.**, a Delaware corporation ("Assignee").

$\underline{\mathbf{W}} \underline{\mathbf{I}} \underline{\mathbf{T}} \underline{\mathbf{N}} \underline{\mathbf{E}} \underline{\mathbf{S}} \underline{\mathbf{E}} \underline{\mathbf{T}} \underline{\mathbf{H}}$:

WHEREAS, Assignors, Assignee, and Lentigen Technology, Inc., a Delaware corporation ("LTI" and, together with Assignee, the "Purchasers"), are parties to that certain Asset Purchase Agreement dated as of May 30, 2014 (the "Purchase Agreement") providing, among other things, for the transfer by Assignors to Assignee of the Assigned Patents (defined below).

NOW, THEREFORE, in consideration of the promises and other valuable consideration to Assignors paid by the Purchasers under the Purchase Agreement, at or before the execution and delivery hereof, the receipt and sufficiency of which is hereby acknowledged by Assignors, the parties agree as follows:

- Section 1.1 Lentigen irrevocably assigns to Assignee:
 - (a) the entire right, title and interest, everywhere in the world, to
- (i) the patents and pending patent applications more specifically set forth in Schedule A attached hereto and incorporated herein by reference,
- (ii) any existing patent applications and/or existing patents that may claim priority from the items in (a) (including but not limited to continuations, divisions, substitutes, reissues, reexaminations, or extensions thereof, together with all priority rights and foreign counterpart applications under any existing or future international patent conventions, agreements or treaties),
- (iii) any patent that may be granted on any patent application in subsections 1.1(a)(i) or (ii) above, and
- (iv) any other rights in the inventions described in any of subsections 1.1(a)(i), (ii) or (iii) above, including rights to future patent applications and all rights of cooperation assigned or granted by a third party
- (all of the foregoing in this <u>Section 1.1</u>, collectively, the "<u>Assigned Lentigen Patents</u>");
- (b) the right to sue third parties for infringement (including but not limited to past, present and future infringement, damages and injunctive relief) of any of

the Assigned Patents based on activities occurring prior to the Effective Date hereof or hereafter; and

- (c) any current or future right to receive royalties based on any of the foregoing.
 - Section 1.2 GBP irrevocably assigns to Assignee:
 - (a) the entire right, title and interest, everywhere in the world, to
- (i) the patents and pending patent applications more specifically set forth in <u>Schedule B</u> attached hereto and incorporated herein by reference,
- (ii) any existing patent applications and/or existing patents that may claim priority from the items in (a) (including but not limited to continuations, divisions, substitutes, reissues, reexaminations, or extensions thereof, together with all priority rights and foreign counterpart applications under any existing or future international patent conventions, agreements or treaties),
- (iii) any patent that may be granted on any patent application in subsection 1.2(a)(i) or (ii) above, and
- (iv) any other rights in the inventions described in any of subsections 1.2(a)(i), (ii) or (iii) above, including rights to future patent applications and all rights of cooperation assigned or granted by a third party
- (all of the foregoing in this <u>Section 1.2</u>, collectively, the "<u>Assigned GBP Patents</u>"; Assigned Lentigen Patents and Assigned GBP Patents, collectively, "<u>Assigned Patents</u>");
- (b) the right to sue third parties for infringement (including but not limited to past, present and future infringement, damages and injunctive relief) of any of the Assigned Patents based on activities occurring prior to the Effective Date hereof or hereafter; and
- (c) any current or future right to receive royalties based on any of the foregoing.
- Section 2. Each Assignor agrees upon the request (and at the expense) of Assignee (or its successors, assigns, or legal representatives) to, and if such Assignor is unable or unwilling to do so authorizes Assignee to act in such Assignor's name to: (i) execute all oaths, assignments, powers and other documents, (ii) testify in any proceedings and otherwise take any action, and (iii) otherwise fully cooperate with Assignee, in each case to the extent reasonably necessary to perform such Assignor's obligations hereunder in connection with securing, perfecting, enforcing and defending the Assigned Patents and Assignee's rights related to this Assignment, and in furtherance of the foregoing Assignor hereby appoints Assignee as such Assignor's agent and

attorney in fact for, and grants to Assignee a power-of-attorney with full power of substitution, to execute, deliver and file any documents, and perform any acts, Assignee would otherwise lawfully be obligated to execute, deliver, file or perform pursuant to this Section 2, with the same legal force and effect as if executed, delivered, filed or performed by such Assignor, and such power of attorney shall be deemed coupled with an interest for the purposes of effecting the foregoing assignments.

[Remainder of Page Intentionally Left Blank; Signature Page Follows]

IN WITNESS WHEREOF, and intending to be legally bound hereby, the Assignors and Assignee have caused this Assignment to be executed and delivered by its duly authorized representative as of the day and year first above written.

duly authorized representative as of the day	and year first above written.
	ASSIGNORS:
	LENTIGEN CORPORATION
	By: T Rowensirely Name: TIMOTHY RAVENSIRET Title: CEO
STATE OF MARYLAND)	
COUNTY OF Montgomery)ss.:)
On this day of Available 2014, before appeared frontly cavers for personally kn satisfactory evidence) to be the person whose acknowledged to me that he executed the sa signature on the instrument the person, or the executed the instrument. Witness my hand and official seal Notary Public	GBP IP CORP. By:
STATE OF MARYLAND))cc ·
COUNTY OF Montgomusy)ss.:)
On this day of wost, 2014, before appeared in Ravenscroft, personally kn satisfactory evidence) to be the person whose acknowledged to me that he executed the sa	e me, the undersigned notary public, personally own to me (or proved to me on the basis or name is subscribed to the within instrument and time in his authorized capacity and that by his e entity upon behalf of which the person acted

[PATENT ASSIGNMENT SIGNATURE PAGE]

ASSIGNEE:

MILTENYI BIOTEC TECHNOLOGY,

INC.,

Name: <u>Stefan Miltenyi</u> Title: <u>President</u>

[PATENT ASSIGNMENT SIGNATURE PAGE]

IN WITNESS WHEREOF, and intending to be legally bound hereby, the Assignors and Assignee have caused this Assignment to be executed and delivered by its duly authorized representative as of the day and year first above written.

ASSIGNORS:

LENTIGEN CORPORATION

	By: Name:
	Title:
STATE OF MARYLAND)	
COUNTY OF)ss.:)
appeared, personant personan	14, before me, the undersigned notary public, personally conally known to me (or proved to me on the basis of on whose name is subscribed to the within instrument and ted the same in his authorized capacity and that by his on, or the entity upon behalf of which the person acted.
Witness my hand and official seal.	
Notary Public	
	GBP IP CORP.
	By:
	Name: Title:
STATE OF MARYLAND)	
COUNTY OF)ss.:)
appeared, personant personan	14, before me, the undersigned notary public, personally bonally known to me (or proved to me on the basis of on whose name is subscribed to the within instrument and ted the same in his authorized capacity and that by his on, or the entity upon behalf of which the person acted.
Witness my hand and official seal.	
Notary Public	

[PATENT ASSIGNMENT SIGNATURE PAGE]

ASSIGNEE:	
MILTENYI BIOTEC TECHNOLOG	ξY
INC.,	
Ву:	
Name: Stefan Miltenyi	
Title: President	

SCHEDULE A

Assigned Lentigen Patents

Category A Patents

- 1. Lentigen 1: Lentiviral Vectors and Their Use
 - 1.1 PCT Publication No. WO 2006/089001 (International Application No. PCT/US2006/05431) (US Patent Application No. 11/884,639)
 - 1.2 National Stage Applications pending in:

United States, Europe, Canada, Australia, New Zealand (abandoned), Mexico, Japan, Norway, Russian Federation (abandoned), India, China, South Korea

- 2. Lentigen 9: Non-integrating HIVVector-Vaccine for Prevention of AIDS
 - 2.1 United States Provisional Application (61/160,285) filed March 13,2009
 - 2.2 United States Provisional Application (61/166,769) filed April 5,2009
 - 2.3 United States Provisional Application (61/167,088) filed April 6,2009
 - 2.4 PCT App. No. PCT/US 10/27262 filed March 13, 2010 for "Non-integrating Retroviral Vector Vaccines"
- 3. Lentigen 10: Advanced Prime and Boost Vaccine
 - 3.1 United States Provisional Application 61/436,828 filed on January 27,2011.
 - 3.2 PCT App. No. PCT/US12/23015 was filed on January 27,2012

Please see attached detail spreadsheet for more information

SCHEDULE B

Assigned GBP Patents

Category A Patents

- 1. CELL13 Family: Method for Production of High Titer Virus and High Efficiency Retroviral Mediated Transduction of Mammalian cells
 - 1.1 United States Patents

5,834,256

5,686,279

5,858,740

6;051,427

6,218,187

0,210,107

6,506,604

7,252,991

1.2 Foreign Counterparts

Australia - Patent Nos. 699660; 721208; and 742403

Canada - Application #2164835 pending

Europe – Patent EP071020 B1

Germany - Patent 69435316.7

France - Patent 710280

Great Britain - 710280

Japan - Application #7-502161 pending

Korea - Patent No. 10-355423

New Zealand - PatentNos. 269019; 316389; 505145; and 505146

Singapore - Patent No. 55158

- 2. CELL 85 Family: Method and Means for Producing High Titer, Safe, Recombinant Lentivirus Vectors
 - 2.1 United States Patents

5,994,136

6,165,782

6,428,953

6,924,144

7,083,981

- 2.2 United States Application No. 11/460,136 published as patent application 200802868362.3
- 2.3 Foreign Counterparts

Australia - Patent No. 751985

Canada - Application Pending

Europe - Patent No. 1036182 B1 UK - Patent No. 1036182 Germany - Patent No. 69838758.9 France - Patent No. 1036182 Switzerland - Patent No. 1036182 Japan - Application # 2000-539150 pending Singapore - Patent No. 73931

- CELL93 Family: Selection System for Generating Efficient Packaging Cells for Lentiviral Vectors
 - 3.1 United States Patent No. 6,797,512
 - 3.2 Foreign Counterparts

Canada - Application # 2349617 pending

Europe - PatentNo. 1129100 B1

United Kingdom - Patent 1129100

Germany - Patent 69936531.7

France - Patent 1129100

Switzerland - Patent 1129100

Japan - Application # 2000-582408 pending

- 4. CELL101 Family: Methods and Means for Producing High Titer, Safe, Recombinant Lentivirus Vectors
 - 4.1 United States Patent No. 7,250,299
 - 4.2 United States Application No. 11/781,094 published as application 20080241929
 - 4.3 Foreign Counterparts Australia Patent No. 778698

Canada - Application # 2370103 pending

Europe - Patent No. 1171624 Bl; and Application No. 07012545.5

UK-Patent No. 1171624

Germany - Patent No. 60035676.0-008

France – Patent No. 1171624

Switzerland - Patent No. 1171624

Israel - Application #146144 pending

Japan - Application #2000-615781 pending

- 5. CELL107 Family: Lentiviral Vectors Encoding Clotting Factors for Gene Therapy
 - 5.1 United States Patents

6,808,905

7,179,903

5.2 United States Application Publication No. US 2007/0178592 (11/626,192) - Liver specific transcriptional enhancer

5.3 Foreign Counterparts

Europe - Application #02751970.1 pending

- 6. CELL129 Family: Pseudotyped Retroviral Vectors
 - 6.1 United States Patent No. 6,863,884
- 7. CELL130 Family: Lentiviral Vector Particles Resistant to Complement Inactivation
 - 7.1 United States Patent 6,790,641
 - 7.2 Foreign Counterpart

Europe - Application # 03726520.4 pending

7.3 Foreign Counterpart Europe - Application Pending

Please see attached detail spreadsheet for more information

		-								Retroviral Packaging System)	applications imarked "Hilled" High Efficiency	yiated bates	.,				Advanced Prime and Boost Vaccine											Non-Integrating Retroviral Vector Vaccines				*****									Leniviral vectors and their Use	
												CELL 13	CELL GENESYS -				Lentigen 10		WWW.									Lentigen 9													replicen 1	25 A 15 A
	7-502161						94921953.9	2229847	12164835	39383/00 *	. 96/90989		72462/94		13/752,568	_I. PCT/US12/23015	61/436,828	2012140691		CN 102438858 A			EP20/51533	13/256,216	US2010027262	61/167,088	61/166,769	61/160,285	US2008708434	11/864639	6735210.4	10-2007-7021145	200680012679.80	T4081/CHENP/2007	2007134371	20074654	2007-556283	MX/a/2007/010008	561074	8728130002	12,597,928	1
-																										-			20080254008	1		10-2007-0114157								9,000,000		S ON THE LAND OF THE
0 600677	4409631			1028U	710280	69435316.7	710280			742403	721208		099669																									297134		2000214270		
2	Granted			_			Granted	Abandoned	Saued	Granted	Granted		Granted									-	-						 ankidan di di serengan di s	pending	pending		pending	pending			Pending	issued		issued	Sugued	4
7	TP	LU	Š	GB	FR	2	170	CA	CA		ΑU		ΑU		us	PCT		Russia	indis	China	Canada		rP C	Su	-				Ö	US	EPO	KR	S	Ž	R	Č	50	×	NZ	ò	ξ	
120	10-Jun-1984						10-Jun-1894	21-/wg-1996	P661-Unf-01	10-Oct-2000	21-Aug-1996		10-Jun-1994		23-Jul-2013	27-Jan-2012	27-Jan-2011						-	13-Mar-2010	01.07-JPW-51.	6-Apr-2009	5-Apr-2009	13-Mar-2009	75-Feb-2006	16-Aug-2007	16-Feb-2006	16-Feb-2006	16-Feb-2006	16-Feb-2006	16-Feb-2006	16-Feb-2006	16-Feb-2006	16-Feb-2006	16-Feb-2006	10-7-000	10-100-2000	Co As Est Mine
												onna	nnne.					-		2-May-12			-									29-Nov-2007		nananana.				-				OALE S
							24-001-2010		5-Jan-2010	18-Apr-2002	72-00-2000		25-Mar-1999																									115-Mar-12		71,470,71	40	S Collection of the State of
2000				ľ	-		10-Jun-2014	21-Aug-2016	10-Jun-2014	21-Aug-2016	21-Aug-2016		10-Jun-2014	-		-					†								16-F80-2026		16-Feb-2026	16-Feb-2026	16-Feb-2026	16-Feb-2026	16-Feb-2026	36-Feb-2026	16-Feb-2026	16-Feb-2026	16-Feb-2026	0302-09 I-01	GODG TO SE	48.F04.3008
								Abandoned		This may have expry on Jun 10, 2014	This may have explry on Jun 10, 2014			PARTICIPATION OF THE PARTICIPA			Provisional Hilfing		Ť							Provisional Filing	Provisional Filing	Provisional Filing	Priority applications are U.S. Provisional Application Nos. 60(£53,386, fleef Feb. 1-6, 2005; 60(£60,310, fleef Mar. 10, 2005; 60(£60,516, fleef May 18, 2005; and 60(723,788, filed Oct. 5, 2005			Abandoned	Responding to Examiner May 2010	Requested examination Feb 2009	Abandoned	Apandoned	Pending	Granted	Abandoned	Giniaga	Liednesiae avenuelium	Permission examination

				iter, Sale, Recombinant Lentivirus Vectors	Methods and Means for Producing High						Packaging Calls for Lambural Vactors	Selection System for Generaling Efficient					•									Safe, Recombinant Lentvirus Vectors	Method and Means for Producing High Titer.		•												Mennel	
				CELT 101	CELL GENESYS -				anna da ang		CELL 93	CELL GENESYS -										*****					CELL GENESYS -															
7012545.5	7012545.5	7012545.5	926354.2	2370103	44897/00	09/831623	60/108169	US99/24018	2000-582408	99962651.8	2803417	2349617	111/460136	11/186497	10/192085	09/604,013	09/271,365	08/989394	200003296-1	US98/25719	2000-7006425	2010-158304	2000-539150		98962894.6	2314609	18034/99	0000010101	USB4/0666/	10/260516	09/944411	09/266596	08/517488	08/438582	08/258152	08/076299	9608353-0	505146	505145	316389 *	269019	95.705608
			1171624					WC00029421	2002530057	1129100			20080286836	20050255597	20020173030				WO 99/3125	WO99/31251					1036182A1																	www
			1171624	2370103	778698	6797512			4482639	1129100				7083981	6924144	6428953	6165782	5994136	73931	-			4640742	1171624	1036182		751985			7252991	8506604	6218187	6051427	5858740	5686279	5834256	55158	505146	505145	316389	1269019	10-355423
		Gramled	benssi	penss	Issued	 issued	Expired	Published	Issued	Issued	Fending	Pending	Pending	Issued	fssued	Issued	betissi	Issued	lasued	Published	Abandoned	Abandoned	Issued	Issued	parissi	Pending	Issued	v outsitory	Published	Granted	Granted	Granted	Granted	Granted	Gränted	Granted						
DE	2	Ţ.	T TO	Ş	ν	SO	SU	PCT	Ū	Ę	Ç	Š	S	S	S	SU	US	S	SG	PCT	XX	<u></u>	ЭP	Ę	m m	Ç	AU		200	8	S	S.	SU	US	US	ES.	SG	R	NZ	NZ	ZNZ	天汉
		26-Jun-2007	26-Apr-2000	26-Apr-2000	26-Apr-2000	12-Sep-2001	13-Nov-1998	12-Nov-1999	12-Nov-1999	112-Nov-1999	11-Jan-2013	12-Nov-1999	26-301-2006	21-Jul-2005	10-Jul-2002	26-Jun-2000	18-Mar-1999	12-Dec-1997	11-Dec-1998	11-Dec-1996	11-Dec-1998	aravan.	11-Dec-1998		11-Dec-1998	11-Dec-1998	11-Dec-1998		10-200-1004	1-Sep-2002	4-Sep-2001	11-Mar-1999	21-Aug-1995	10-May-1995	10-Jun-1994	11-Jun-1983	10-Jun-1994	14-Jun-2000	14-Jun-2000	21-Aug-1996	10-Jun-1994	11-Dec-1995
			16-Jan-2002	-		 		25-May-2000	17-Sep-2002	05-Sep-2001			8002-v0N-02	1	21-Nov-2002					24-Jun-1988											-					-				-		
			25-101-2007		14-Apr-2005	28-Sep-2004				11-Jul-2007				01-Aug-2006	02-Aug-2005	06-Aug-2002	26-Dec-2000	30-Nov-1999	10-Apr-2002				10-Dec-10		21-Nov-2007		22-Jul-2002			7-Aug-Zuur	14-Jan-2003	17-Apr-2001	18-Apr-2000	12-Jan-1999	11-Nov-1997	10-Nov-1998	23-Jan-2002	13-May-2002	5-Feb-2002	7-Dec-2000	6-Jul-2000	24-Sep-2002
			23-Apr-2013	2-Aug-11	26-Apr-2020	12-Sep-2021			2-Apr-10	12-Nov-2019				12-Dec-2017	26-Jun-2020	12-Dec-2017	12-Dec-2017	12-Dec-2017	11-Dec-2018				11-Dec-2018		11-Dec-2018		11-Dec-2018	1		11-Jun-2013	11-Jun-2013	11-Jun-2013	11-Jun-2013	13-Jan-2016	11-Nov-2014	10-Nov-2015	10-Jun-2014		Expired?	Expired?	10-Jun-2014	
A CONTRACTOR OF THE CONTRACTOR		awaiting Office Action	validated countries; FR, DE, CH, GB						notification of allowance issued; issue fee	validated countries: FR, DE, CH, GB	Jan 2013 Division for non-selected claims	Nov 2012 restriction requirement	KUE Hed Sep 15, 2011									Divisional filed white parent case 2000- 539150 was on appeal of final rejection		,	Pending validation in countries: PR, DE, CH, CB																	Allowed to expire on Sep 24, 2012

															Nucleic Acid		importance = 2				Complement Inactivation CELL 130	Lentiviral Vector Particles Resistant to CELL GE	CE11.128	Corr of				Using Same	Transcriptional Enhancer and Melhods of	Legiviral Vectors Featuring Liver Specific CELL 107	g Clotting Factors Liver Specific						
				516	9				15	9	5	ů,			CELL GENESYS - 7			on.		12		CELL GENESYS - 3		1010	L			-2	Ċı		CELL GENESYS - 2			- Ch	1		
		08/40/42/	DIACTACA .	08/540750	ONCENTAGE CONCENTRATE	08-014-019	20000	96933140	96933140.4	96933140.4	69631795.8-08	96933140.4	2233867	61272/00	1681/96		10/425323	60/376767	11113966	10012126.8	US03/13271	3726520.4	10/420324	outor or oc	0022200	11/626192	10/685457	10/145289	60/291083	US02/15062	2751970.1	1781,294	10/031639	60/131671	US00/11097	2000-615781	146144
					110000	WICOTH DEDO		8647189								-	03-0207445				03/093417	1497437	03-0207436	2007100		2007-0178592	04-0259208	03-0077812		02/092134	1395283-A1	20080241929			WO0068759	2003508017	
			\(\frac{1}{2}\)	6013518	Caration	8 1000(%	740000	864148	8/1459	871459	871459	871459		758600	720993		6790641					_	0853804	2000		7745179	7179903	6808905			1395293		7250299			4,979,857	145144
-		Madellonia	<u> </u>	is is in a	Section of	Dublishod	Special	Hevoked	Revoked	Revoked	Revoked	Revoked	lssued	issued	Issued	-	ssued	Expired			Published	Pending	29062	Contract	CVI	issued	issued	ssued	Expired	Published	issued	Pending	Issued	Expired	Published	Dawoiiki	Granied
		8	7	77 5		1	őř	ľ	-		R		C _A	AU	æ		S	ક્ર	픚	ΕP	PCT	EP.	u a	2	ō	S				암	ij	2	SR	cs	PCT	Ť	
		0.000	4000	FOR-1985	Action and	28-San-1006	26 Con 1006	26-Sep-1995	129-Sep-1996	28-Sep-1996	27-Sep-1996	26-Sep-1896	26-Sep-1996	22-Sep-2000	26-Sep-1996		29-Apr-2003	11-May-2002		29-Apr-2003	29-Apr-2003	28-Apr-2003	5007-10V-EZ	and a second	13/10/2003	23-Jan-2007	6-Jul-2004	14-May-2002	114-May-2001	14-May-2002	14-May-2002	ZU-Ju-ZUU?	9-May-2002	28-Apr-1999	26-Apr-2000	25-Apr-2000	26-Apr-2000
					100 100	10-005-1907											06-Nov-2003			!	13-Nov-2003	19-Jan-2005	CONZ-ADAL-CO	2002		2-Aug-2007	23-Dec-2004	24-Apr-2003		21-Nov-2002	10-Mar-2004	Renz-ton-2			09-Nov-2000	U4-MBT-ZUUS	
				17-Jan-2000				US-MBF-ZUG Q	03-3481-2004	03-Mar-2004	03-Mar-2004	03-Mar-2004	11-Sep-12		22-Jun-2000		14-Sep-2004						A0-8491-2000	2000 100		29-Jun-2010		26-0c1-2004			22~Jul-2009		31-Jul-2007			21-Apr-12	1-reb-11
				8-06-2015	B-Oct-2015	d-Cotten in	R CM 2015	1							26-Sep-2016		29-Apr-2023	01-May-2003					7207-Ida-62	COUNTY TOOL	01_k4au_2003	26-Oct-2024	26-Oct-2024	14-May-2022	14-May-2002		14-May-22		26-Apr-2020	29-Apr-Zuou		co-Api-20	200
	AAAAAAAA		2015	Note: Royalty payments due to Dec 10				Reversed by Board of Appears	Revoked by Isoard of Appears	Revoked by Board of Appeals	Revoked by Board of Appeals	Revoked by Board of Appeals	response to pending office action filed Apoil 2009 awaiting response.							Divisional of 3726520.4		awaiting decision of Board of Appeals									to be validated in Switzerland, Germany, France, UK and Ireland	riidi ejeccon wii be appealed – ii issued will explie Apr 26, 2020				Allowed	

-			 		
			Therapeutic Alkylating Agents	Therapy to Protect from Toxicity of	Use of Mutant Alkyltransferases for Gene CASE WESTERN
			UNIVERSITY	RESERVE	
EP0910246	US 1997/004917	5,965,126			08/620,969
EΡ	(PC)	Su	 		Sul
	25-Mar-1997				25-Mar-1996
28-Apr-1999 18-Aug-2010	12-1		 		
18-Aug-2010		12-Oct-1999			
		25-Mar-2016			
					Regular patent filing

RECORDED: 03/23/2016